Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Front Immunol. 2020 Oct 7;11:572677. doi: 10.3389/fimmu.2020.572677. eCollection 2020.
With the emerging of highly active antiretroviral therapy, HIV-1 infection has transferred from a fatal threat to a chronic disease that could be managed. Nevertheless, inextricable systemic immune activation and chronic inflammation despite viral suppression render patients still at higher risk of HIV-1-associated non-AIDS complications. Immunometabolism has nowadays raised more and more attention for that targeting metabolism may become a promising approach to modulate immune system and play a role in treating cancer, HIV-1 infection and autoimmune diseases. HIV-1 mainly infects CD4+ T cells and accumulating evidence has brought to light the association between T cell metabolism reprogramming and HIV-1 pathogenesis. Here, we will focus on the interplay of glycometabolism reprogramming of T cells and HIV-1 infection, making an effort to delineate the possibility of utilizing immunometabolism as a new target towards HIV-1 management and even sterilizing cure through eliminating viral reservoir.
随着高效抗逆转录病毒疗法的出现，HIV-1 感染已从致命威胁转变为可控制的慢性疾病。然而，尽管病毒得到抑制，但不可避免的全身性免疫激活和慢性炎症仍使患者面临更高的 HIV-1 相关非艾滋病并发症风险。免疫代谢近年来引起了越来越多的关注，因为靶向代谢可能成为调节免疫系统的一种有前途的方法，并在治疗癌症、HIV-1 感染和自身免疫性疾病方面发挥作用。HIV-1 主要感染 CD4+T 细胞，越来越多的证据表明 T 细胞代谢重编程与 HIV-1 发病机制之间存在关联。在这里，我们将重点关注 T 细胞糖代谢重编程与 HIV-1 感染的相互作用，努力描绘通过消除病毒库，利用免疫代谢作为 HIV-1 管理甚至根治的新靶点的可能性。
